New hope for psoriasis: Immune-Targeting drug under study
NCT ID NCT04645355
First seen Apr 09, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This study looks at how the drug guselkumab affects the immune system in people with plaque or guttate psoriasis. About 25 adults with recent-onset guttate or plaque psoriasis will receive treatment. The goal is to understand changes in immune cells that cause psoriasis symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States
Conditions
Explore the condition pages connected to this study.